Organization
Hopital Bretonneau
3 abstracts
Abstract
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).Org: Hopital Bretonneau,
Abstract
Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.Org: Memorial Sloan Kettering Cancer Center, Centre Hospitalier Lyon Sud, Hopital Bretonneau, Karolinska University Hospital at Huddinge, University of Navarra,
Abstract
Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.Org: Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Vrije Universiteit Amsterdam, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania,